Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Protalix BioTherapeutics, Inc. (PLX) had Weighted-Average Shares Outstanding (Diluted) of 83.05M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$33.75M |
|
$18.32M |
|
$4.13M |
|
$29.62M |
|
$12.60M |
|
$21.15M |
|
$-0.01M |
|
$21.14M |
|
$21.14M |
|
$18.32M |
|
$18.32M |
|
$18.32M |
|
$18.32M |
|
$21.15M |
|
$21.55M |
|
79.85M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
83.05M |
$0.23 |
|
$0.22 |
|
| Balance Sheet Financials | |
$86.36M |
|
$5.15M |
|
$15.98M |
|
$102.34M |
|
$27.39M |
|
-- |
|
$7.72M |
|
$35.11M |
|
-- |
|
$67.23M |
|
$67.23M |
|
80.57M |
|
| Cash Flow Statement Financials | |
$22.02M |
|
$4.22M |
|
$0.15M |
|
$14.68M |
|
$41.00M |
|
$26.32M |
|
$0.53M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
87.77% |
|
62.65% |
|
62.65% |
|
-- |
|
62.64% |
|
54.27% |
|
$21.26M |
|
-- |
|
-- |
|
-- |
|
0.33 |
|
0.14 |
|
11.48 |
|
7.84 |
|
-- |
|
27.25% |
|
17.90% |
|
27.25% |
|
$0.83 |
|
$0.26 |
|
$0.27 |
|